EditorialA New Generation of Coronary Vasodilators in Stress Perfusion Imaging
Section snippets
Selective A-2a Agonists
Currently, there are 3 such agents in phase III clinical trials. These agents are hoped to have the desirable features but none of the side effects of adenosine, because that is what selectivity implies. These agents are regadenoson, binodenoson, and apadenoson. A forth agent (CGS21680) was studied only in an animal model and is not likely to enter clinical testing.8 The 3 agonists share a common feature of selectivity, but they do differ in affinity, onset of action, duration of hyperemia, and
References (13)
- et al.
Pharmacologic stress testing: mechanism of action, hemodynamic responses, and results in detection of coronary artery disease
J Nucl Cardiol
(1994) - et al.
Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry
J Am Coll Cardiol
(1994) - et al.
Initial clinical experience with regadenoson, a novel selective A2A agonist for pharmacologic stress single-photon emission computed tomography myocardial perfusion imaging
J Am Coll Cardiol
(2005) - et al.
Coronary circulation responses to binodenoson, a selective adenosine A2a receptor agonist
Am J Cardiol
(2007) - et al.
Effect of caffeine on ischemia detection by adenosine single-photon emission computed tomography perfusion imaging
J Am Coll Cardiol
(2006) - et al.
The effects of plasma insulin and glucose on myocardial blood flow in patients with type 1 diabetes mellitus
J Am Coll Cardiol
(2005)
Cited by (10)
Therapeutic potential of adenosine analogues and conjugates
2011, Pharmacological ReportsCitation Excerpt :However, further studies are required to improve its affinity and selectivity to A2A. Selective A2A adenosine receptor agonists are a new class of coronary vasodilators used in stress perfusion imaging with radiotracers [47]. The myocardial perfusion imaging stress test is a noninvasive way to assess blood flow to the heart muscle to detect coronary artery disease.
Coronary Artery Disease Detection: Pharmacologic Stress SPECT. Pharmacologic Stress SPECT.
2010, Clinical Nuclear Cardiology: State of the Art and Future DirectionsCoronary artery disease detection: Pharmacologic stress SPECT
2010, Clinical Nuclear CardiologyDifferences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus
2009, American Heart JournalSafety of regadenoson as a pharmacologic stress agent in patients with chronic kidney and pulmonary disease
2016, Myocardial Perfusion Imaging (MPI): Performance, Potential Risks and Outcomes